Shiquandabutang Treatment Of Gastrointestinal Cancer Cachexia Syndrome Clinical Study

Objective:To study Shiquandabutang treatment of gastrointestinal cancer cachexia syndrome clinical value.Methods:According to randomized controlled method, would be consistent with cancer cachexia syndrome in September 2007 to December 2009 were divided into 2 groups. The treatment group taking Shiquandabutang; the control group taking megestrol acetate, two groups were given basic nutritional support therapy. After 4 weeks of treatment were observed before and after treatment of appetite, food intake, body weight, albumin, immune cells, clinical symptoms, subcutaneous fat condition, quality of life and side effects after treatment were measured. Application SPSS13.0 statistical software for statistical analysis of data, whether observed Shiquandabutang clinical value.Results:Shiquandabutang After treatment, the appetite, body weight, serum albumin, hemoglobin, subcutaneous fat, immune cells, KPS score and so on are until the increase or improvement (P<0.05) and compared with the control group there are significant differences after (P<0.05)Conclusion:Shiquandabutang treatment can significantly improve cachexia in patients with malignant appetite, weight gain, enhance immunity, improve quality of life, and better than megestrol acetate...